glp-1 employer healthcare costs Employers Grapple with Claims versus Outcomes of Drugs Employer healthcare spending in 2025:

As Ricks put it to me: We can make basically as much as we need. Given it is in a pill and not an injection, which reduces supply chain needs around plastics and cold storage, and that is does not have special instructions to take it, it is likely to become a popular choice for primary care [physicians] as they wont have to demonstrate pen usage, etc., Dr

Developed by Eli Lilly, retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors a mechanism that sets it apart from currently approved medicines such as semaglutide and tirzepatide

The momentum has only accelerated, contributing to the rising cost of treating diabetes

Improved Metabolic Health With tirzepatide, patients have noticed improvements in metabolic health indicators such as blood sugar levels, blood pressure, cholesterol profiles, and inflammation markers